Novartis In-licenses Cytos#8217; Smoking Vaccine
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 84 (Table of Contents)
Published: 1 Jun-2007
DOI: 10.3833/pdr.v2007.i84.330 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
This feature discusses the recent US$497 M licensing deal between Cytos Biotechnology and Novartis for CYT002-NicQb, a therapeutic vaccine in Phase II clinical development for the treatment of nicotine addiction...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS